Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2008

View Archived Issues

Preclinical profile of CAL-101 in hematological cancers disclosed

New BACE1 inhibitors for Alzheimer's disease reported in recent Medivir patent

Novel DBH inhibitors patented by Bial - Portela

MT-103 converts MRD-positive ALL into MRD-negative ALL in phase II study

NDA for crofelemer in HIV-associated diarrhea expected in 2010

Progen and Avexa sign exclusive and binding merger implementation agreement

Drais and Diatos sign global license agreement for cancer drug DTS-108

Avigen sells rights to blood coagulation drug AV-513 to Baxter

FDA approves Novartis' Gleevec for recurrence following surgical removal of a GIST

Ligand licenses worldwide rights to LGD-4665 and other ligand thrombopoietin molecules to GSK

Clinuvel submits IND for confirmatory PK trial of photoprotective afamelanotide

FDA approves Vasovist intravascular contrast agent

FDA approves Zolpimist oral spray for insomnia

Wyeth acquires Thiakis and obesity drug TKS-1225

FDA grants approval to StemCells to initiate phase I clinical trial of HuCNS-SC in PMD

European CHMP formally adopts positive opinion for IDM Pharma's Mepact in osteosarcoma

DMC recommends continuation of phase III trial of Pharmexa's Telovac in pancreatic cancer

Lundbeck initiates phase II clinical trial of Lu-AA-39959 in bipolar I or II disorder

FDA approves Ferring's degarelix for advanced prostate cancer

FDA approves Latisse for hypotrichosis of eyelashes

Additional indication for Fastic/Starsis approved in Japan

AEG-35156 plus chemotherapy effective in some patients with refractory acute myeloid leukemia

Pyronaridine/artesunate demonstrates efficacy against P. falciparum and P. vivax malaria

Malaria vaccine AMA1-C1/ISA 720 evaluated in phase I study

Novel MGL/FAAH inhibitors emerge from sanofi-aventis R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...